SEC 13F Intelligence

Managers / Q1 2020 · view latest →

FRAZIER MANAGEMENT LLC

CIK 0001032165 · 601 UNION ST, SUITE 2110, SEATTLE, WA, 98101 · 2066217200

Reported Value
$882M
Q1 2020
Positions
25
Filings on Record
16
2019–present window
Filed
May 13, 2020
original filing

Summary

Frazier Management LLC reported $882M in U.S.-listed holdings across 25 positions for Q1 2020.

The portfolio is heavily concentrated: ARQT alone accounts for 35.6% of reported value.

Compared with Q4 2019, the fund opened 8 new positions and exited 3.

Portfolio Metrics

Turnover
+20.6%
vs prior filed quarter
Top-10 Concentration
+91.2%
share of reported value
Largest Position
+35.6%
Arcutis Biotherapeutics
New / Exited
8 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $388MQ4 ’18Q1 ’19: $415MQ2 ’19: $390MQ2 ’19Q3 ’19: $320MQ4 ’19: $596MQ4 ’19Q1 ’20: $882MQ2 ’20: $1.1BQ2 ’20Q3 ’20: $1.1BQ4 ’20: $1.3BQ4 ’20Q1 ’21: $1.2BQ2 ’21: $1.1BQ2 ’21Q3 ’21: $1.2BQ4 ’21: $1.3BQ4 ’21Q2 ’22: $1MQ3 ’22: $0Q3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 85.3%Other: 14.7%
  • Common Stock · 85.3% · $752M
  • Other · 14.7% · $130M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ARQTARCUTIS BIOTHERAPEUTICS INCNEW+10.54M10.54M+$314M$314M
PASSAGE BIO INCNEW+5.01M5.01M+$79M$79M
SNDXSYNDAX PHARMACEUTICALS INCNEW+990.7K990.7K+$11M$11M
TREURTRILLIUM THERAPEUTICS INCNEW+2.44M2.44M+$10M$10M
RCKTROCKET PHARMACEUTICALS INCNEW+210.0K210.0K+$3M$3M
VTV THERAPEUTICS INCNEW+1.06M1.06M+$2M$2M
SIERRA ONCOLOGY INCNEW+202.8K202.8K+$2M$2M
BELLICUM PHARMACEUTICALS INCNEW+105.1K105.1K+$495,000$495,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

25 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM35.62%$314M10.54M
2PHATPHATHOM PHARMACEUTICALS INChistory →COM21.32%$188M7.28M
3PASSAGE BIO INCCOM8.95%$79M5.01M
4IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM5.94%$52M1.75M
5MIRMMIRUM PHARMACEUTICALS INChistory →COM5.66%$50M3.57M
6KRYSKRYSTAL BIOTECH INChistory →COM4.39%$39M895.0K
7ANABANAPTYSBIO INChistory →COM3.71%$33M2.32M
8TRANSLATE BIO INCCOM2.47%$22M2.18M
9COLLCOLLEGIUM PHARMACEUTICAL INChistory →COM1.75%$15M943.7K
10ADVERUM BIOTECHNOLOGIES INCCOM1.42%$12M1.28M
11GRITSTONE ONCOLOGY INCCOM1.36%$12M2.06M
12SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.23%$11M990.7K
13TREURTRILLIUM THERAPEUTICS INChistory →COM NEW1.08%$10M2.44M
14ALPINE IMMUNE SCIENCES INCCOM0.84%$7M2.57M
15MILLENDO THERAPEUTICS INCCOM0.84%$7M1.40M
16APTINYX INCCOM0.78%$7M3.19M
17ITERUM THERAPEUTICS PLCSHS0.47%$4M1.54M
18CIDARA THERAPEUTICS INCCOM0.37%$3M1.31M
19ALLENA PHARMACEUTICALS INCCOM0.36%$3M3.33M
20RCKTROCKET PHARMACEUTICALS INCCOM0.33%$3M210.0K
21ENTASIS THERAPEUTICS HLDGS ICOM0.31%$3M1.05M
22NABRIVA THERAPEUTICS PLCSHS0.28%$2M4.26M
23VTV THERAPEUTICS INCCL A0.23%$2M1.06M
24SIERRA ONCOLOGY INCCOM NEW0.23%$2M202.8K
25BELLICUM PHARMACEUTICALS INCCOM NEW0.06%$495,000105.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$01Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1M1Aug 10, 202213F-HRchanges · EDGAR ↗
Q1 2022Under review2May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.3B43Feb 8, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B41Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B34Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.2B35May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.3B35Feb 11, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B31Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B26Aug 4, 202013F-HRchanges · EDGAR ↗
Q1 2020$882M25May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$596M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$320M19Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$390M18Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$415M17May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$388M17Feb 11, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.